SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced today that it has entered into securities purchase agreements with certain institutional and accredited investors to issue, in a private placement, 8,235,297 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 8,235,297 shares of common stock, at a purchase price of $0.425 per share of common stock (or pre-funded warrant) and associated warrant, for expected gross proceeds to Histogen of approximately $3.5 million, before deducting placement agent fees and other offering expenses payable by the Company. The warrants have an exercise price of $0.425 per share of common stock, will be exercisable commencing six months and one day following the date of issuance for a period…
Click here to view original post
News
Histogen to Present at the Canaccord Genuity 41st Annual Growth Conference
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen,… Click here to view original post… […]
News
Histogen Announces Closing of $3.5 Million Private Placement
SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced today the closing of its previously announced private placement for the issuance and sale… Click here to view original post… […]
News
Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen,… Click here to view original post… […]
